Baseline patient characteristics in Genomics-only and Clinical outcomes cohorts.
| Cohort . | Tumor type and MTAP status . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDAC . | IHCC . | HCC . | CRC . | GEAC . | ||||||
| Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | |
| Genomics-only cohorta | ||||||||||
| Number of case (% within tumor type) | 12 319 (78.4) | 3401 (21.6) | 4352 (84.7) | 785 (15.3) | 1306 (97.6) | 32 (2.4) | 35 537 (98.9) | 396 (1.1) | 6143 (91.3) | 589 (8.7) |
| Gender (% male) | 52.9 | 52.4 | 48.9 | 51.1 | 75.3 | 59.4 | 55.6 | 58.3 | 86.4 | 83.7 |
| Age, median, years (range) | 67 (23-89) | 67 (25-89) | 66 (18-89) | 66 (18-89+) | 67 (5-89) | 61.5 (34-83) | 61 (10-89) | 61.5 (21-89) | 66 (22-89) | 65 (21-89) |
| Genomic ancestry, % | ||||||||||
| AFR | 10.1 | 9.8 | 8.8 | 8.0 | 13.9 | 12.5 | 12.5 | 10.9 | 2.8 | 2.0 |
| AMR | 7.5 | 80.9 | 11.9 | 10.8 | 12.5 | 12.5 | 10.1 | 10.9 | 5.1 | 5.6 |
| EAS | 3.2 | 4.4 | 4.3 | 6.4 | 6.7 | 9.4 | 40.5 | 45.5 | 1.1 | 0.8 |
| EUR | 78.5 | 77.1 | 73.6 | 74.2 | 65.3 | 65.6 | 72.4 | 73.5 | 90.6 | 91.0 |
| SAS | 0.7 | 0.7 | 1.4 | 0.5 | 1.6 | 0 | 0.9 | 0.3 | 0.4 | 0.5 |
| Clinical outcomes cohort | ||||||||||
| Number of cases (% within tumor type) | 11 | 21 | 49 | 21 | ||||||
| Gender (% male) | 72.7 | 33.3 | 50.0 | 33.3 | ||||||
| Age, median, years (range) | 62.7 (52.4-74.4) | 60.8 (19.0-70.9) | 57.3 (23.6-77.2) | 54.0 (23.3-80.5) | ||||||
| Ethnicity | ||||||||||
| Caucasian | 9 | 14 | 40 | 17 | ||||||
| African | 1 | 5 | 1 | 1 | ||||||
| Hispanic | 1 | 2 | 3 | 1 | ||||||
| Asian | 0 | 0 | 5 | 2 | ||||||
| NGS panel used, % | ||||||||||
| FoundationOne CDx | 5 | 17 | 43 | 21 | ||||||
| Perthera | 2 | 1 | 0 | 0 | ||||||
| Tempus xT | 3 | 3 | 6 | 0 | ||||||
| MSK IMPACT | 1 | 0 | 0 | 0 | ||||||
| Cohort . | Tumor type and MTAP status . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDAC . | IHCC . | HCC . | CRC . | GEAC . | ||||||
| Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | |
| Genomics-only cohorta | ||||||||||
| Number of case (% within tumor type) | 12 319 (78.4) | 3401 (21.6) | 4352 (84.7) | 785 (15.3) | 1306 (97.6) | 32 (2.4) | 35 537 (98.9) | 396 (1.1) | 6143 (91.3) | 589 (8.7) |
| Gender (% male) | 52.9 | 52.4 | 48.9 | 51.1 | 75.3 | 59.4 | 55.6 | 58.3 | 86.4 | 83.7 |
| Age, median, years (range) | 67 (23-89) | 67 (25-89) | 66 (18-89) | 66 (18-89+) | 67 (5-89) | 61.5 (34-83) | 61 (10-89) | 61.5 (21-89) | 66 (22-89) | 65 (21-89) |
| Genomic ancestry, % | ||||||||||
| AFR | 10.1 | 9.8 | 8.8 | 8.0 | 13.9 | 12.5 | 12.5 | 10.9 | 2.8 | 2.0 |
| AMR | 7.5 | 80.9 | 11.9 | 10.8 | 12.5 | 12.5 | 10.1 | 10.9 | 5.1 | 5.6 |
| EAS | 3.2 | 4.4 | 4.3 | 6.4 | 6.7 | 9.4 | 40.5 | 45.5 | 1.1 | 0.8 |
| EUR | 78.5 | 77.1 | 73.6 | 74.2 | 65.3 | 65.6 | 72.4 | 73.5 | 90.6 | 91.0 |
| SAS | 0.7 | 0.7 | 1.4 | 0.5 | 1.6 | 0 | 0.9 | 0.3 | 0.4 | 0.5 |
| Clinical outcomes cohort | ||||||||||
| Number of cases (% within tumor type) | 11 | 21 | 49 | 21 | ||||||
| Gender (% male) | 72.7 | 33.3 | 50.0 | 33.3 | ||||||
| Age, median, years (range) | 62.7 (52.4-74.4) | 60.8 (19.0-70.9) | 57.3 (23.6-77.2) | 54.0 (23.3-80.5) | ||||||
| Ethnicity | ||||||||||
| Caucasian | 9 | 14 | 40 | 17 | ||||||
| African | 1 | 5 | 1 | 1 | ||||||
| Hispanic | 1 | 2 | 3 | 1 | ||||||
| Asian | 0 | 0 | 5 | 2 | ||||||
| NGS panel used, % | ||||||||||
| FoundationOne CDx | 5 | 17 | 43 | 21 | ||||||
| Perthera | 2 | 1 | 0 | 0 | ||||||
| Tempus xT | 3 | 3 | 6 | 0 | ||||||
| MSK IMPACT | 1 | 0 | 0 | 0 | ||||||
aThe FoundationOne CDx NGS panel was used for the entire Genomics-only cohort: 64 860 (100%).
Abbreviations: MTAP, methylthioadenosine phosphorylase; PDAC, pancreatic ductal adenocarcinoma; IHCC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma; CRC, colorectal carcinoma; GEAC, gastroesophageal adenocarcinoma; AFR, African; AMR, admixed American; EAS, East Asian; EUR, European; SAS, South Asian.
Baseline patient characteristics in Genomics-only and Clinical outcomes cohorts.
| Cohort . | Tumor type and MTAP status . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDAC . | IHCC . | HCC . | CRC . | GEAC . | ||||||
| Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | |
| Genomics-only cohorta | ||||||||||
| Number of case (% within tumor type) | 12 319 (78.4) | 3401 (21.6) | 4352 (84.7) | 785 (15.3) | 1306 (97.6) | 32 (2.4) | 35 537 (98.9) | 396 (1.1) | 6143 (91.3) | 589 (8.7) |
| Gender (% male) | 52.9 | 52.4 | 48.9 | 51.1 | 75.3 | 59.4 | 55.6 | 58.3 | 86.4 | 83.7 |
| Age, median, years (range) | 67 (23-89) | 67 (25-89) | 66 (18-89) | 66 (18-89+) | 67 (5-89) | 61.5 (34-83) | 61 (10-89) | 61.5 (21-89) | 66 (22-89) | 65 (21-89) |
| Genomic ancestry, % | ||||||||||
| AFR | 10.1 | 9.8 | 8.8 | 8.0 | 13.9 | 12.5 | 12.5 | 10.9 | 2.8 | 2.0 |
| AMR | 7.5 | 80.9 | 11.9 | 10.8 | 12.5 | 12.5 | 10.1 | 10.9 | 5.1 | 5.6 |
| EAS | 3.2 | 4.4 | 4.3 | 6.4 | 6.7 | 9.4 | 40.5 | 45.5 | 1.1 | 0.8 |
| EUR | 78.5 | 77.1 | 73.6 | 74.2 | 65.3 | 65.6 | 72.4 | 73.5 | 90.6 | 91.0 |
| SAS | 0.7 | 0.7 | 1.4 | 0.5 | 1.6 | 0 | 0.9 | 0.3 | 0.4 | 0.5 |
| Clinical outcomes cohort | ||||||||||
| Number of cases (% within tumor type) | 11 | 21 | 49 | 21 | ||||||
| Gender (% male) | 72.7 | 33.3 | 50.0 | 33.3 | ||||||
| Age, median, years (range) | 62.7 (52.4-74.4) | 60.8 (19.0-70.9) | 57.3 (23.6-77.2) | 54.0 (23.3-80.5) | ||||||
| Ethnicity | ||||||||||
| Caucasian | 9 | 14 | 40 | 17 | ||||||
| African | 1 | 5 | 1 | 1 | ||||||
| Hispanic | 1 | 2 | 3 | 1 | ||||||
| Asian | 0 | 0 | 5 | 2 | ||||||
| NGS panel used, % | ||||||||||
| FoundationOne CDx | 5 | 17 | 43 | 21 | ||||||
| Perthera | 2 | 1 | 0 | 0 | ||||||
| Tempus xT | 3 | 3 | 6 | 0 | ||||||
| MSK IMPACT | 1 | 0 | 0 | 0 | ||||||
| Cohort . | Tumor type and MTAP status . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDAC . | IHCC . | HCC . | CRC . | GEAC . | ||||||
| Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | Intact . | Loss . | |
| Genomics-only cohorta | ||||||||||
| Number of case (% within tumor type) | 12 319 (78.4) | 3401 (21.6) | 4352 (84.7) | 785 (15.3) | 1306 (97.6) | 32 (2.4) | 35 537 (98.9) | 396 (1.1) | 6143 (91.3) | 589 (8.7) |
| Gender (% male) | 52.9 | 52.4 | 48.9 | 51.1 | 75.3 | 59.4 | 55.6 | 58.3 | 86.4 | 83.7 |
| Age, median, years (range) | 67 (23-89) | 67 (25-89) | 66 (18-89) | 66 (18-89+) | 67 (5-89) | 61.5 (34-83) | 61 (10-89) | 61.5 (21-89) | 66 (22-89) | 65 (21-89) |
| Genomic ancestry, % | ||||||||||
| AFR | 10.1 | 9.8 | 8.8 | 8.0 | 13.9 | 12.5 | 12.5 | 10.9 | 2.8 | 2.0 |
| AMR | 7.5 | 80.9 | 11.9 | 10.8 | 12.5 | 12.5 | 10.1 | 10.9 | 5.1 | 5.6 |
| EAS | 3.2 | 4.4 | 4.3 | 6.4 | 6.7 | 9.4 | 40.5 | 45.5 | 1.1 | 0.8 |
| EUR | 78.5 | 77.1 | 73.6 | 74.2 | 65.3 | 65.6 | 72.4 | 73.5 | 90.6 | 91.0 |
| SAS | 0.7 | 0.7 | 1.4 | 0.5 | 1.6 | 0 | 0.9 | 0.3 | 0.4 | 0.5 |
| Clinical outcomes cohort | ||||||||||
| Number of cases (% within tumor type) | 11 | 21 | 49 | 21 | ||||||
| Gender (% male) | 72.7 | 33.3 | 50.0 | 33.3 | ||||||
| Age, median, years (range) | 62.7 (52.4-74.4) | 60.8 (19.0-70.9) | 57.3 (23.6-77.2) | 54.0 (23.3-80.5) | ||||||
| Ethnicity | ||||||||||
| Caucasian | 9 | 14 | 40 | 17 | ||||||
| African | 1 | 5 | 1 | 1 | ||||||
| Hispanic | 1 | 2 | 3 | 1 | ||||||
| Asian | 0 | 0 | 5 | 2 | ||||||
| NGS panel used, % | ||||||||||
| FoundationOne CDx | 5 | 17 | 43 | 21 | ||||||
| Perthera | 2 | 1 | 0 | 0 | ||||||
| Tempus xT | 3 | 3 | 6 | 0 | ||||||
| MSK IMPACT | 1 | 0 | 0 | 0 | ||||||
aThe FoundationOne CDx NGS panel was used for the entire Genomics-only cohort: 64 860 (100%).
Abbreviations: MTAP, methylthioadenosine phosphorylase; PDAC, pancreatic ductal adenocarcinoma; IHCC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma; CRC, colorectal carcinoma; GEAC, gastroesophageal adenocarcinoma; AFR, African; AMR, admixed American; EAS, East Asian; EUR, European; SAS, South Asian.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
